1. Home
  2. WINA vs SNDX Comparison

WINA vs SNDX Comparison

Compare WINA & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Winmark Corporation

WINA

Winmark Corporation

HOLD

Current Price

$426.96

Market Cap

1.5B

ML Signal

HOLD

Logo Syndax Pharmaceuticals Inc.

SNDX

Syndax Pharmaceuticals Inc.

HOLD

Current Price

$20.35

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WINA
SNDX
Founded
1988
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Other Specialty Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.3B
IPO Year
1993
2016

Fundamental Metrics

Financial Performance
Metric
WINA
SNDX
Price
$426.96
$20.35
Analyst Decision
Strong Buy
Analyst Count
0
12
Target Price
N/A
$36.92
AVG Volume (30 Days)
84.2K
2.4M
Earning Date
10-15-2025
11-03-2025
Dividend Yield
2.66%
N/A
EPS Growth
2.56
N/A
EPS
11.21
N/A
Revenue
$84,517,400.00
$111,304,000.00
Revenue This Year
$7.05
$620.14
Revenue Next Year
$3.60
$115.42
P/E Ratio
$38.01
N/A
Revenue Growth
3.35
595.65
52 Week Low
$295.79
$8.58
52 Week High
$527.37
$20.59

Technical Indicators

Market Signals
Indicator
WINA
SNDX
Relative Strength Index (RSI) 51.25 69.27
Support Level $405.86 $18.36
Resistance Level $432.21 $20.20
Average True Range (ATR) 15.68 0.98
MACD 2.91 0.15
Stochastic Oscillator 68.18 92.43

Price Performance

Historical Comparison
WINA
SNDX

About WINA Winmark Corporation

Winmark Corp is a franchisor of value-oriented retail store concepts that buy, sell, and trade gently used merchandise. The company has one reportable segment including Franchising and one non-reportable segment Leasing. The franchising segment franchises value-oriented retail store that buys, sell, trade, and consign merchandise as well as provide strategic consulting services relating to franchising. The leasing segment includes middle-market equipment leasing business and small-ticket financing business. It generates a majority of its revenue from the Franchising segment.

About SNDX Syndax Pharmaceuticals Inc.

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

Share on Social Networks: